vyleesi
Palatin Technologies (Palatin)–a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics–developed bremelanotide for the treatment of Female Sexual Dysfunction. They engaged Brandsymbol to develop the proprietary brand name that would introduce this product to the world. Despite their initial “high-risk” name candidate being rejected, Palatin was able quickly to have an alternate, equally compelling brand name approved: Vyleesi™. Carl Spana, Ph.D., CEO and President of Palatin said,
“Going forward, the first quarter of the calendar year 2019 could bring FDA approval for Vylessi™ – a significant milestone and major inflection point for Palatin, its employees, its shareholders, and most importantly, the thousands of premenopausal women seeking treatment for HSDD in the U.S.”